Mai, Knut <br/><br/>
Rosiglitazone decreases 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue.  [electronic resource] 

 -  Clinical endocrinology  Sep 2007 
 - 419-25 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0300-0664 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2265.2007.02903.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>11-beta-Hydroxysteroid Dehydrogenase Type 1--genetics<br/>Adrenocorticotropic Hormone--blood<br/>Blood Glucose--metabolism<br/>Enzyme Activation--drug effects<br/>Gene Expression Regulation, Enzymologic--drug effects<br/>Glucose Tolerance Test<br/>Humans<br/>Hydrocortisone--blood<br/>Hyperglycemia--drug therapy<br/>Hypoglycemic Agents--administration & dosage<br/>Insulin--blood<br/>Insulin Resistance--physiology<br/>Liver--drug effects<br/>Male<br/>Middle Aged<br/>Rosiglitazone<br/>Subcutaneous Fat--drug effects<br/>Thiazolidinediones--administration & dosage